NCT06211751

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

A Phase Ib Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of TQB3909 Tablets Combined With TQB3702 Tablets in Hematologic Malignancy Subjects.

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.

Conditions

• Hematologic Malignancy

Interventions

Type	Name	Description
DRUG	TQB3909 tablets	TQB3909 is a protein inhibitor.
DRUG	TQB3702 tablets	TQB3702 is a kinase inhibitor.

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-12-01
• Completion: 2026-06-01
• First posted: 2024-01-18
• Last updated: 2024-01-18

Locations

1 site across 1 country: China